Recombinant factor VIIa (rFVIIa, Novoseven®, Novo
Nordisk®, Denmark) is established for the management
of bleeding episodes in haemophiliac patients with inhibitors.
Interest has been growing in the use of this drug
for the management of severe intractable bleeding following
major trauma and surgery.
Advertisement
For UK healthcare professionals only